JP2010536396A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536396A5
JP2010536396A5 JP2010522371A JP2010522371A JP2010536396A5 JP 2010536396 A5 JP2010536396 A5 JP 2010536396A5 JP 2010522371 A JP2010522371 A JP 2010522371A JP 2010522371 A JP2010522371 A JP 2010522371A JP 2010536396 A5 JP2010536396 A5 JP 2010536396A5
Authority
JP
Japan
Prior art keywords
protein
antibody
cells
cell
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536396A (ja
Filing date
Publication date
Priority claimed from EP07115227A external-priority patent/EP2031064A1/de
Application filed filed Critical
Publication of JP2010536396A publication Critical patent/JP2010536396A/ja
Publication of JP2010536396A5 publication Critical patent/JP2010536396A5/ja
Pending legal-status Critical Current

Links

JP2010522371A 2007-08-29 2008-08-28 タンパク質力価を増加させる方法 Pending JP2010536396A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115227A EP2031064A1 (de) 2007-08-29 2007-08-29 Verfahren zur Steigerung von Proteintitern
PCT/EP2008/061310 WO2009027471A1 (de) 2007-08-29 2008-08-28 Verfahren zur steigerung von proteintitern

Publications (2)

Publication Number Publication Date
JP2010536396A JP2010536396A (ja) 2010-12-02
JP2010536396A5 true JP2010536396A5 (enExample) 2011-10-13

Family

ID=39107125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522371A Pending JP2010536396A (ja) 2007-08-29 2008-08-28 タンパク質力価を増加させる方法

Country Status (6)

Country Link
US (1) US20100297697A1 (enExample)
EP (2) EP2031064A1 (enExample)
JP (1) JP2010536396A (enExample)
KR (1) KR20100046219A (enExample)
CA (1) CA2696809A1 (enExample)
WO (1) WO2009027471A1 (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP1878747A1 (en) * 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
ES2687808T3 (es) * 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2455403A1 (en) * 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9631216B2 (en) 2011-04-29 2017-04-25 Biocon Research Limited Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
WO2013004841A1 (en) 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
EP2771031B1 (en) 2011-10-28 2018-04-18 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
EP2807188B1 (en) 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
CN104619853B (zh) * 2012-04-23 2021-10-12 帝斯曼知识产权资产管理有限公司 多肽表达方法
PL3489254T3 (pl) * 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
MY186864A (en) * 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
EP3116906A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US11090381B2 (en) 2015-09-01 2021-08-17 Oncoqr Ml Gmbh Coiled-coil connector
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
MA51223A (fr) 2017-11-29 2020-10-07 Prothena Biosciences Ltd Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
EP3774879B1 (en) * 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants
SG11202104549TA (en) 2018-11-08 2021-05-28 Prothena Biosciences Ltd Antibodies recognizing tau
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
EP3995582B1 (en) 2019-07-01 2026-04-22 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
AU2021297540A1 (en) 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
US20240010735A1 (en) 2020-12-24 2024-01-11 Eisai R&D Management Co., Ltd. Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis
EP4269588A4 (en) 2020-12-24 2025-04-23 Eisai R&D Management Co., Ltd. ANTI-EPHA4 ANTIBODIES
CN118234864A (zh) 2021-11-11 2024-06-21 卫材R&D管理有限公司 抗EphA4抗体
WO2025059486A1 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Anti-tdp-43 antibodies and uses thereof
EP4777522A2 (en) 2023-09-15 2026-07-22 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
CN122070299A (zh) 2023-09-15 2026-05-19 普罗塞纳生物科学有限公司 细胞穿透剂及其用途
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG60017B2 (bg) * 1988-09-28 1993-06-30 Eli Lilly And Company Метод за намаляване хетерогенността на моноклонални антитела
EP1423431B1 (en) * 2001-04-13 2010-06-16 Biogen Idec MA Inc. Antibodies to vla-1
ES2371072T3 (es) * 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
JP2008525452A (ja) * 2004-12-22 2008-07-17 イーライ リリー アンド カンパニー Ｇｌｐ−１類似体融合蛋白質製剤
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途

Similar Documents

Publication Publication Date Title
JP6573331B2 (ja) 同起源の抗体可変領域遺伝子セグメントをクローニングおよび発現させるための迅速な方法
JP2024026255A5 (enExample)
JP2019031529A5 (enExample)
JP2010523085A5 (enExample)
US9458244B2 (en) Single chain multivalent binding protein compositions and methods
CN104854133A (zh) 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
NZ701825A (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2020125120A1 (zh) 一种抗体文库的构建方法及其应用
JP2012514997A5 (enExample)
JP2020505927A5 (enExample)
Okazaki et al. Efficient heterologous expression and secretion in Aspergillus oryzae of a llama variable heavy-chain antibody fragment VHH against EGFR
CN101413002A (zh) 表达抗体或抗体类似物的重组克鲁维酵母菌及其构建方法与应用
Diepenbruck et al. Productivity and quality of recombinant proteins produced by stable CHO cell clones can be predicted by transient expression in HEK cells
CA2861393A1 (en) Tools and methods for expression of membrane proteins
JP2024037844A (ja) 試料中のポリペプチドの検出または捕捉において使用するための抗体、組成物、および試料中のポリペプチドの検出または捕捉のための方法
CN106478773B (zh) 一种人工合成的新型信号肽
CN104558181A (zh) 靶向b淋巴瘤细胞的人源单链抗体
EP2990485A1 (en) Fd chain gene or l chain gene each capable of increasing secretion amount of fab-type antibody
US11946074B2 (en) Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
EP4037699A1 (en) Protein binders to irhom2 epitopes
US10793619B2 (en) Preparation and selection of cells for producing bispecific antibodies
CN106478774B (zh) 一种用于蛋白质表达的信号肽
LT2005043A (en) Process for preparing monoclonal antibodies; hybridoma cell lines generated by this process and recombinant chimeric virus-like particles with inserted foreign protein fragments as immunogenes to generate hybridomas by this process
CN104558180B (zh) 靶向t淋巴细胞的人源单链抗体
CN115572331A (zh) 一种具有增强FcRn受体结合的突变子